Literature DB >> 27346637

Biliary atresia: A comprehensive review.

Bhanumathi Lakshminarayanan1, Mark Davenport2.   

Abstract

Biliary atresia presents as an obliterative cholangiopathy with neonatal jaundice and pale stools. The disease exhibits aetiological heterogeneity with a multiplicity of potential causative factors, both developmental and environmental. A number of clinical variants making up a minority of all cases can be defined relatively precisely which match suggested aetiology better although in most it still remains speculative. These include the syndromic form (BASM), the cystic form and those associated with CMV IgM antibodies. We review not only the clinical evidence for a developmental or an immune-mediated aetiology perhaps triggered by perinatal viral exposure but also several other recently suggested concepts such as microchimerism, gene susceptibility and environmental toxins.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biliary atresia; Immune response; Inflammation; Kasai portoenterostomy; Microchimerism

Mesh:

Substances:

Year:  2016        PMID: 27346637     DOI: 10.1016/j.jaut.2016.06.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  54 in total

1.  A wave of Foxp3+ regulatory T cell accumulation in the neonatal liver plays unique roles in maintaining self-tolerance.

Authors:  Mingyang Li; Weijia Zhao; Yifan Wang; Lixue Jin; Gaowen Jin; Xiuyuan Sun; Wei Wang; Ke Wang; Xi Xu; Jie Hao; Rong Jin; Wenxian Fu; Ying Sun; Yingjun Chang; Xiaojun Huang; Xuyu Zhou; Hounan Wu; Kunshan Zhang; Qing Ge
Journal:  Cell Mol Immunol       Date:  2019-06-06       Impact factor: 11.530

Review 2.  Sclerosing and obstructive cholangiopathy in biliary atresia: mechanisms and association with biliary innate immunity.

Authors:  Kenichi Harada
Journal:  Pediatr Surg Int       Date:  2017-10-16       Impact factor: 1.827

3.  Association of T-helper cell cytokine level with age in patients with biliary atresia: a preliminary study.

Authors:  Fu-Bang Li; Xiao-Li Shu; Wei-Zhong Gu; Xiao-Xia Zhao; Shou-Jiang Huang; Hong Zhao; Ke-Rong Peng; Jin-Fa Tou
Journal:  World J Pediatr       Date:  2018-08-29       Impact factor: 2.764

4.  Single nucleotide polymorphisms within Adducin 3 and Adducin 3 antisense RNA1 genes are associated with biliary atresia in Thai infants.

Authors:  Wison Laochareonsuk; Piyawan Chiengkriwate; Surasak Sangkhathat
Journal:  Pediatr Surg Int       Date:  2018-03-05       Impact factor: 1.827

Review 5.  Update on investigations pertaining to the pathogenesis of biliary atresia.

Authors:  Alexandra Kilgore; Cara L Mack
Journal:  Pediatr Surg Int       Date:  2017-10-24       Impact factor: 1.827

Review 6.  Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Lindsey Kennedy; Suthat Liangpunsakul; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2019-04-22       Impact factor: 6.902

7.  Ultrasound characteristics combined with gamma-glutamyl transpeptidase for diagnosis of biliary atresia in infants less than 30 days.

Authors:  Guotao Wang; Nan Zhang; Xiaoer Zhang; Wenying Zhou; Xiaoyan Xie; Luyao Zhou
Journal:  Pediatr Surg Int       Date:  2021-05-19       Impact factor: 1.827

8.  The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients.

Authors:  Akhmad Makhmudi; Reinaldo Supanji; Bayu Pratama Putra
Journal:  Pediatr Surg Int       Date:  2019-09-23       Impact factor: 1.827

Review 9.  Newborn screening for biliary atresia in the United States.

Authors:  Cat Goodhue; Michael Fenlon; Kasper S Wang
Journal:  Pediatr Surg Int       Date:  2017-10-05       Impact factor: 1.827

10.  MRI-based decision tree model for diagnosis of biliary atresia.

Authors:  Yong Hee Kim; Myung-Joon Kim; Hyun Joo Shin; Haesung Yoon; Seok Joo Han; Hong Koh; Yun Ho Roh; Mi-Jung Lee
Journal:  Eur Radiol       Date:  2018-02-23       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.